Psyence Biomedical (NASDAQ:PBM) Upgraded to “Hold” at Wall Street Zen

Posted by ABMN Staff on Jun 6th, 2026

Psyence Biomedical (NASDAQ:PBM – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Psyence Biomedical in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

View Our Latest Research Report on PBM

Psyence Biomedical Trading Down 4.9%

Shares of NASDAQ:PBM opened at $3.51 on Friday. Psyence Biomedical has a 52 week low of $1.92 and a 52 week high of $74.94. The company’s 50 day moving average is $4.70 and its two-hundred day moving average is $5.25. The company has a market cap of $3.58 million, a PE ratio of 0.14 and a beta of 1.64.

Institutional Investors Weigh In On Psyence Biomedical

An institutional investor recently bought a new position in Psyence Biomedical stock. Virtu Financial LLC acquired a new stake in Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,325 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.55% of Psyence Biomedical at the end of the most recent quarter. 77.44% of the stock is currently owned by institutional investors and hedge funds.

Psyence Biomedical Company Profile

(Get Free Report)

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.